Novartis Pharmaceuticals Corporation, commonly referred to as Novartis, is a leading global healthcare company headquartered in the United States. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has established a strong presence in key operational regions, including Europe, Asia, and Latin America. Specialising in innovative pharmaceuticals, Novartis focuses on areas such as oncology, cardiology, immunology, and neuroscience. The company is renowned for its unique portfolio of patented medications and cutting-edge therapies, which have significantly advanced patient care. With a commitment to research and development, Novartis has achieved notable milestones, including the introduction of groundbreaking treatments that address unmet medical needs. As a prominent player in the pharmaceutical industry, Novartis continues to enhance its market position through strategic partnerships and a robust pipeline of new products.
How does Novartis Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Novartis Pharmaceuticals Corporation's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
As of the latest available data, Novartis Pharmaceuticals Corporation does not report specific carbon emissions figures. The company is a current subsidiary of Novartis AG, which cascades its climate commitments and emissions data. Novartis AG has set ambitious targets to reduce its carbon footprint, aligning with industry standards and initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). While specific reduction targets for Novartis Pharmaceuticals Corporation are not detailed, the overarching commitments from Novartis AG indicate a strong focus on sustainability and climate action. The company is actively involved in initiatives like RE100, aiming for 100% renewable electricity, and the Race to Zero campaign, which underscores its dedication to achieving net-zero emissions. In summary, while Novartis Pharmaceuticals Corporation does not provide specific emissions data, it benefits from the climate strategies and targets set by its parent company, Novartis AG, reflecting a commitment to reducing carbon emissions and enhancing sustainability within the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis Pharmaceuticals Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.